Answers are grounded in this paper and cite their sources.
Although three dual orexin receptor antagonists (DORAs), suvorexant, lemborexant, and daridorexant, are currently available and widely used to treat insomnia, the differences in their elimination half-lives are not sufficient. As a result, clinicians have limited ability to tailor therapy to individual sleep complaints. The emergence of vornorexant, with a notably short half-life comparable to that of zolpidem, may substantially expand the clinical utility of DORAs. This broader spectrum of pharmacokinetic profiles enables more individualized treatment strategies that align with patients' specific sleep complaints. This approach, in turn, potentially reshapes the therapeutic paradigm of insomnia management. However, several challenges remain to be addressed in order to fully realize the clinical potential of DORAs. This review identifies four key challenges requiring resolution to advance their optimal use in clinical practice. • Vornorexant is a new DORA with the shortest half-life among DORAs. • Emerging of vornorexant enhances utility of DORAs. • There are four challenges to advance DORA's optimal use in clinical practice.
No takes yet. Share an insight, caveat, or question.
Chaki et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: